The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 - Therapy

Canadian Journal of Cardiology

Volumn 23, Issue 7, 2007, Pages 539-550

  Khan, Nadia A ^a,u   Hemmelgarn, Brenda ^b   Padwal, Raj ^c   Larochelle, Pierre ^d   Mahon, Jeff L ^e   Lewanczuk, Richard Z ^c   McAlister, Finlay A ^c   Rabkin, Simon W ^a   Hill, Michael D ^b   Feldman, Ross D ^f   Schiffrin, Ernesto L ^g   Campbell, Norman R C ^b   Logan, Alexander G ^h   Arnold, Malcolm ^e   Moe, Gordon ⁱ   Campbell, Tavis S ^j   Milot, Alain ^k   Stone, James A ^b   Jones, Charlotte ^b   Leiter, Lawrence A ⁱ   Ogilvie, Richard J ^l   Herman, Robert J ^b   Hamet, Pavel ^d   Fodor, George ^m   Carruthers, George ⁿ   Culleton, Bruce ^b   Burns, Kevin D ^o   Ruzicka, Marcel ^o   deChamplain, Jacques ^g   Pylypchuk, George ^p   Gledhill, Norm ^q   Petrella, Robert ^e   Boulanger, Jean Martin ^b   Trudeau, Luc ^r   Hegele, Robert A ^e   Woo, Vincent ^s   McFarlane, Phil ^h   Touyz, Rhian M ^t   Tobe, Sheldon W ^h   more..

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

^f ROBARTS RESEARCH INSTITUTE   (Canada)

^g CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ ST MICHAEL'S HOSPITAL   (Canada)

^j UNIVERSITY OF CALGARY   (Canada)

^k UNIVERSITÉ LAVAL   (Canada)

^l UNIVERSITY HEALTH NETWORK   (Canada)

^m UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

ⁿ UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^o UNIVERSITY OF OTTAWA   (Canada)

^p UNIVERSITY OF SASKATCHEWAN   (Canada)

^q YORK UNIVERSITY   (Canada)

^r MCGILL UNIVERSITY   (Canada)

^s UNIVERSITY OF MANITOBA   (Canada)

^t OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^u ST PAUL S HOSPITAL   (Canada)

more..

Author keywords

Antihypertensive drugs; Blood pressure; Guidelines; High blood pressure; Hypertension; Lifestyle interventions

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROPOIETIN; FELODIPINE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PLACEBO; PRAZOSIN; SPIRONOLACTONE; TACROLIMUS; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN; VERAPAMIL;

ADD ON THERAPY; AEROBIC EXERCISE; ALCOHOL CONSUMPTION; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CANADA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COCHRANE LIBRARY; COMORBIDITY; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DIET THERAPY; DIETARY REFERENCE INTAKE; DRUG ANTAGONISM; DRUG CHOICE; DRUG INDICATION; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; HEALTH EDUCATION; HEALTH PROGRAM; HIGH RISK PATIENT; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; HYPOKALEMIA; KIDNEY DYSFUNCTION; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MEDLINE; META ANALYSIS; MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHEOCHROMOCYTOMA; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; RENOVASCULAR HYPERTENSION; STRESS MANAGEMENT; SYSTEMATIC REVIEW; SYSTOLIC HYPERTENSION; WEIGHT REDUCTION;

EID: 34250824791     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(07)70798-5     Document Type: Article

References (43)

1. Murray CJ, Lauer JA, Hutubessy RC, et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: A global and regional analysis on reduction of cardiovascular-disease risk. Lancet 2003;361:717-25. (Erratum in 2005;366:204).
2. Yusuf S, Hawken S, Ounpuu S, et al; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004;364:937-52.
3. World Health Organization. Preventing chronic diseases: A vital investment. (Version current at April 26, 2007).
4. Stamler R. Implications of the INTERSALT study. Hypertension 1991;17(1 Suppl):116-20
5. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-74.
6. Appel LJ, Sacks FM, Carey VJ, et al; OmniHeart Collaborative Research Group. Effects of protein, mono-unsaturated fat, and carbohydrate intake on blood pressure and serum lipids. JAMA 2005;294:2455-64.
7. He J, Gu D, Wu X, et al. Effect of soybean protein on blood pressure: A randomized, controlled trial. Ann Intern Med 2005:143:1-9.
8. Rasmussen BM, Vessby B, Uusitupa M, et al; The KANWU Study Group. Effects of dietary saturated, monounsaturated, and n-3 fatty acids on blood pressure in healthy subjects. Am J Clin Nutr 2006;83:221-6.
9. He FJ. MacGregor, GA. Effect of longer-term modest salt reduction on blood pressure. Cochrane Database Syst Rev 2004;(3):CD004937
10. Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A; FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: A randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 2005;23:2157-72.
11. Julius S, Kjeldsen SE, Weber M, et al; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004;363:2022-31.
12. McAlister FA, Sackett DL. Active-control equivalence trials and antihypertensive agents. Am J Med 2001;111:553-8.
13. Miller ER Jr, Erlinger TP, Young DR, Prokopowicz GP, Appel LJ. Lifestyle changes that reduce blood pressure: Implementation in clinical practice. J Clin Hypertens (Greenwich) 1999;1:191-8.
14. Appel LJ, Champagne CM, Harsha DW, et al; Writing Group of the PREMIER Collaborative Research Group. Effects of comprehensive lifestyle modification on blood pressure control: Main results of the PREMIER clinical trial. JAMA 2003;289:2083-93.
15. Appel LJ. Lifestyle modification as a means to prevent and treat high blood pressure. J Am Soc Nephrol 2003;14:S99-S102.
16. Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
17. Kemmler W, Lauber D, Weineck J, Hensen J, Kalender W, Engelke K. Benefits of 2 years of intense exercise on bone density, physical fitness, and blood lipids in early postmenopausal osteopenic women: Results of the Erlangen Fitness Osteoporosis Prevention Study (EFOPS). Arch Intern Med 2004;164:1084-91.
18. Koertge J, Weidner G, Elliott-Eller M, et al. Improvement in medical risk factors and quality of life in women and men with coronary artery disease in the Multicenter Lifestyle Demonstration Project. Am J Cardiol 2003;91:1316-22.
19. Sacks FM, Svetkey LP, Vollmer WM, et al; DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001;344:3-10.
20. Appel LJ, Brands MW, Daniels SR, Karanja N, Elmer PJ, Sacks FM; American Heart Association. Dietary approaches to prevent and treat hypertension: A scientific statement from the American Heart Association. Hypertension 2006;47:296-308.
21. US Department of Health and Human Services. Dietary Guidelines for Americans 2005. (Version current at April 26, 2007).
22. Karppanen H, Karppanen P, Mervaala E. Why and how to implement sodium, potassium, calcium, and magnesium changes in food items and diets? J Hum Hypertens 2005;19(Suppl 3):S10-9.
23. Chang HY, Hu YW, Yue CS, et al. Effect of potassium-enriched salt on cardiovascular mortality and medical expenses of elderly men. Am J Clin Nutr 2006;83:1289-96.
24. Touyz RM, Campbell N, Logan A, Gledhill N, Petrella R, Padwal R; Canadian Hypertension Education Program. The 2004 Canadian recommendations for the management of hypertension: Part III - lifestyle modifications to prevent and control hypertension. Can J Cardiol 2004;20:55-9.
25. Khan NA, McAlister FA, Lewanczuk RZ, et al; Canadian Hypertension Education Program. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - therapy. Can J Cardiol 2005;21:657-72.
26. McAlister FA, Levine M, Zarnke KB, et al; Canadian Hypertension Recommendations Working Group. The 2000 Canadian recommendations for the management of hypertension: Part one - therapy. Can J Cardiol 2001;17:543-59.
27. Psaty BP, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NH. Health outcomes associated with various antihypertensive therapies used as first-line agents: A network meta-analysis. JAMA 2003;289:2534-44.
28. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: A quantitative overview updated until 1 March 2003. J Hypertens 2003;21:1055-76.
29. Khan NA, McAlister FA, Campbell NR, et al; Canadian Hypertension Education Program. The 2004 Canadian recommendations for the management of hypertension: Part II - therapy. Can J Cardiol 2004;20:41-54.
30. Messerli FH, Mancia G, Conti CR, et al. Dogma disputed: Can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2004;149:884-93.
31. Lindholm LH, Ibsen H, Dahlof B, et al; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002;359:1004-10.
32. Remuzzi G, Chiurchiu C, Ruggenenti P. Proteinuria predicting outcome in renal disease: Nondiabetic nephropathies (REIN). Kidney Int Suppl 2004;92:S90-6.
33. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001;135:73-87. (Erratum in 2002;137:299).
34. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 2003;361:117-24. (Erratum in 2003;361:1230).
35. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern? Arch Intern Med 2000;160:685-693.
36. McAlister FA, Zarnke KB, Campbell NR, et al; Canadian Hypertension Recommendations Working Group. The 2001 Canadian recommendations for the management of hypertension: Part two - therapy. Can J Cardiol 2002;18:625-41.
37. Alzaid AA. Microalbuminuria in patients with NIDDM: An overview. Diabetes Care 1996;19:79-89.
38. Neil A, Thorogood M, Hawkins M, Cohen D, Potok M, Mann J. A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes Care 1993;16;996-1003.
39. Bakker AJ. Detection of microalbuminuria. Receiver operating characteristic curve analysis favors albumin-to-creatinine ratio over albumin concentration. Diabetes Care 1999;22:307-13.
40. Bakris GL, Gaxiola E, Messerli FH, et al; INVEST Investigators. Clinical outcomes in the diabetes cohort of the INternational VEmpamil SR-Trandolapril study. Hypertension 2004;44:637-42.
41. Scognamiglio R, Negut C, Ramondo A, Tiengo A, Avogaro A. Detection of coronary artery disease in asymptomatic patients with type 2 diabetes mellitus. J Am Coll Cardiol 2006;47:65-71.
42. Khan NA, McAlister FA, Rabkin SW, et al; Canadian Hypertension Education Program. The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - therapy. Can J Cardiol 2006;22:583-93.
43. Sever PS, Dahlof B, Poulter NR, et al; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003;361:1149-58.